1700020O03Rik Activators
RIKEN cDNA 1700020O03 gene product activators comprise an array of chemical compounds that indirectly influence the functional activity of the protein through diverse signaling pathways. Forskolin, a direct adenylyl cyclase stimulant, raises intracellular cAMP levels, which activates protein kinase A (PKA). PKA phosphorylates target proteins, potentially enhancing the activity of RIKEN cDNA 1700020O03 gene product by changing its phosphorylation state, which is central to its function. The suite of chemical activators for the RIKEN cDNA 1700020O03 gene product orchestrates a symphony of intracellular signals that indirectly augment the protein's activity. Forskolin, by increasing cAMP, instigates a cascade where PKA is activated, which may target and phosphorylate the RIKEN cDNA 1700020O03 gene product to enhance its functionality. PMA, acting as a PKC activator, could similarly induce phosphorylation events that promote the protein's activity.
Sphingosine-1-phosphate, through receptor-mediated signaling, and Ionomycin, by escalating calcium levels, might modulate kinases and phosphatases that fine-tune the protein's state and function. IBMX, which preserves cAMP and cGMP levels, could further amplify these PKA or PKG dependent pathways, potentially elevating the RIKEN cDNA 1700020O03 gene product's activity. PI3K inhibitor LY294002, MEK inhibitors U0126, p38 MAPK inhibitor SB203580, and multiple kinase inhibitor EGCG can shift the balance of cellular signaling, which may result in compensatory activation of pathways involving the RIKEN cDNA 1700020O03 gene product. Additionally, Thapsigargin and A23187 dramatically alter calcium homeostasis, which may indirectly lead to the activation of calcium-dependent signaling mechanisms, possibly impacting the RIKEN cDNA 1700020O03 gene product activity. Staurosporine, despite its broad spectrum of kinase inhibition, could inadvertently facilitate the activation of specific pathways or molecules that increase the activity of the RIKEN cDNA 1700020O03 gene product by inhibiting its negative regulators.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC), which may influence the phosphorylation status of the RIKEN cDNA 1700020O03 gene product, thereby potentially enhancing its activity through post-translational modifications. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
This lipid signaling molecule activates sphingosine-1-phosphate receptors, which can trigger downstream signaling cascades including those that may influence the activity of the RIKEN cDNA 1700020O03 gene product through altered lipid signaling. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin acts as an ionophore for calcium, increasing intracellular calcium levels. Elevated calcium can activate calcium-dependent kinases and phosphatases, which may modulate the activity of RIKEN cDNA 1700020O03 gene product. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-specific inhibitor of phosphodiesterases, which prevents the breakdown of cAMP and cGMP, potentially enhancing PKA or PKG signaling pathways that could upregulate the activity of RIKEN cDNA 1700020O03 gene product. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 inhibits PI3K, which might lead to a compensatory enhancement in alternative pathways, potentially including those involving the RIKEN cDNA 1700020O03 gene product. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 specifically inhibits p38 MAPK, potentially altering the signaling landscape to favor the activation of alternative pathways that include RIKEN cDNA 1700020O03 gene product. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG inhibits multiple kinases, which could lead to the selective activation of signaling pathways that involve the RIKEN cDNA 1700020O03 gene product by reducing competitive signaling interactions. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin disrupts calcium stores by inhibiting the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA), which could enhance the activity of RIKEN cDNA 1700020O03 gene product through calcium-dependent signaling pathways. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 is a calcium ionophore that raises intracellular calcium levels, which could activate calcium-dependent signaling pathways and potentially enhance the activity of RIKEN cDNA 1700020O03 gene product. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Although staurosporine is a general kinase inhibitor, it might lead to the selective activation of pathways involving RIKEN cDNA 1700020O03 gene product by disrupting the phosphorylation of competing pathways. | ||||||